ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Arcus Biosciences (RCUS) pipeline and stated timing

Pipeline at a glance

ProgramEventStageStated timingFiling
casdatifan/data readoutStage not stated20268-K ·
casdatifanTopline/data readoutStage not stated20268-K ·
casdatifanTopline/data readoutStage not stated20268-K ·
casdatifanTopline/data readoutStage not stated20268-K ·

Source: ORION, orionbiotechai.com/company/RCUS, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/RCUS

Nearest upcoming stated timing: casdatifan · Topline/data readout · 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

casdatifan

Matched

Topline/data readout2026

Stage: Not stated

Public float: $565,882,788 · as of · SEC filing

In second-line IO-experienced ccRCC, more mature overall response rate data and initial PFS data, including Kaplan-Meier curve(s), for approximately 45 patients treated in the ARC-20 cohort evaluating casdatifan plus cabozantinib. All patients will have had at least 18 months of follow-up.

SEC timing context:

Arcus expects multiple data readouts for casdatifan in 2026:

8-K · Filed · Last checked

Source details

Accession 0001724521-26-000042

casdatifan

Matched

Topline/data readout2026

Stage: Not stated

Public float: $565,882,788 · as of · SEC filing

early efficacy data for the cohort evaluating casdatifan plus zimberelimab

SEC timing context:

Arcus expects multiple data readouts for casdatifan in 2026:

8-K · Filed · Last checked

Source details

Accession 0001724521-26-000042

casdatifan

Matched

Topline/data readout2026

Stage: Not stated

Public float: $565,882,788 · as of · SEC filing

early safety data for the cohort evaluating casdatifan plus zimberelimab plus ipilimumab

SEC timing context:

Arcus expects multiple data readouts for casdatifan in 2026:

8-K · Filed · Last checked

Source details

Accession 0001724521-26-000042

casdatifan

Matched

Topline/data readout2026

Stage: Not stated

Public float: $565,882,788 · as of · SEC filing

In late-line ccRCC, updated data from the ARC-20 monotherapy cohorts, including overall survival data.

SEC timing context:

Arcus expects multiple data readouts for casdatifan in 2026:

8-K · Filed · Last checked

Source details

Accession 0001724521-26-000042

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
casdatifanClinical results2026
“In second-line IO-experienced ccRCC, more mature overall response rate data and initial PFS data, including Kaplan-Meier curve(s), for approximately 45 patients treated in the ARC-20 cohort evaluating casdatifan plus cabozantinib. All patients will have had at least 18 months of follow-up.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

casdatifanClinical results2026
“early efficacy data for the cohort evaluating casdatifan plus zimberelimab”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

casdatifanClinical results2026
“early safety data for the cohort evaluating casdatifan plus zimberelimab plus ipilimumab”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

casdatifanClinical results2026
“In late-line ccRCC, updated data from the ARC-20 monotherapy cohorts, including overall survival data.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained company announcements

Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.

Historical catalog checked .

No historical announcement trail is retained for this company in this catalog.

Selected registry record

Casdatifan · NCT07751250

Condition in the selected registry record
Healthy Participants
Phase in the selected registry record
Phase 1
Identity checked

Original ClinicalTrials.gov record · Open the selected study

Retained company–study identity sources

Scope of retained company and registry evidence

These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.

Coverage and identity checks

Watch RCUS

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for RCUS. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See RCUS in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.